LCA-0321
Asset
Selectively degrades disease-driving thyroid-stimulating hormone receptor autoantibodies through lysosomal targeting.
- Stage
- Phase 1
- Modality
- Not known
- Target
- Not known
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Graves' disease
Phase 1, lyciatx.com, 10 Oct 2026
In the full profile
- Owner and partners1
Every asset’s record: target, stage, trials and the evidence behind it.